Company Drug

CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial – Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis

By Fineline Cube #CF PharmTech #Clinical trial approval / initiation #HKG: 2652

CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.

Regulatory Milestone

ItemDetail
AgencyNMPA (China)
Approval TypeClinical trial authorization (IND)
ProductOlopatadine + mometasone fixed-dose combination
FormulationNasal spray (single-device)
IndicationModerate-to-severe allergic rhinitis
Target PopulationAdults and adolescents ≥12 years
DeveloperCF PharmTech Inc. (Wuxi, China)
Approval DateMarch 2026

Product Profile & Mechanism

ComponentClassMechanismContribution
OlopatadineH1-antihistamine (selective, non-sedating)Blocks histamine H1 receptors; mast cell stabilizationRapid relief of nasal itching, sneezing, rhinorrhea
MometasoneIntranasal corticosteroid (potent, low bioavailability)Anti-inflammatory; reduces nasal mucosa inflammationSustained control of nasal congestion, overall symptom severity

Combination Rationale:

  • Dual pathway blockade: Antihistamine addresses immediate hypersensitivity; corticosteroid targets underlying inflammation
  • Convenience advantage: Single nasal device vs. separate antihistamine and steroid sprays (improved adherence)
  • Efficacy synergy: Fixed-dose timing optimizes pharmacodynamic coordination

Market Context & Competitive Landscape

FactorStrategic Implication
Allergic Rhinitis Burden400+ million affected in China; moderate-to-severe represents 30-40% of diagnosed patients
Standard of CareIntranasal corticosteroids (fluticasone, mometasone) first-line; antihistamines adjunctive
Combination GapNo fixed-dose antihistamine/corticosteroid nasal sprays approved in China; patients use separate devices
Adherence ChallengeComplex multi-spray regimens reduce compliance; simplified single-device improves outcomes
Competitive ThreatsGeneric mometasone flooding market; olopatadine differentiation via combination patent protection

Development Outlook

PhaseTimelineObjectives
Phase I2026Safety, tolerability, pharmacokinetics of combination formulation
Phase II2027-2028Dose-ranging, efficacy vs. monotherapy components
Phase III2028-2029Non-inferiority/superiority vs. free-combination standard of care
NDA Filing2029-2030China approval as first fixed-dose nasal spray for allergic rhinitis

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for CF PharmTech’s olopatadine/mometasone combination. Actual results may differ due to formulation challenges, competitive dynamics, and reimbursement decisions in the respiratory allergy market.-Fineline Info & Tech

2026030900030_cDownload

Related Post

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube

You Missed

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations